Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Federal regulators drew a firm line around medical Сannabis, a hostile bid for Aurora turned more personal, and Q3 2026 earnings showed which operators convert retail traffic into cash. Capital deployment remains disciplined while balance sheets face relentless scrutiny. Operators run tighter operations while regulators maintain stubborn boundaries. From contested takeover fights in Canada to administrative hurdles in Washington, D.C., here’s what moved Cannabis and Psychedelics industries forward over the past week.

1.  Curaleaf Keeps Pressing Aurora

Curaleaf’s hostile bid for Aurora Cannabis grew more heated. On October 19, Curaleaf accused Aurora’s board of opening its data room to unnamed third parties while denying access to the only bidder with a binding offer. The enhanced proposal gives Aurora holders 0.4013 Curaleaf shares plus $1 in cash per share, capped at $6, which Curaleaf calls an 86% premium. It stays open through December 4.

A week later, the Alberta Securities Commission dismissed Curaleaf’s application to halt Aurora’s at-the-market share program, which the regulator found compliant. Curaleaf says that ruling settles a procedural point and leaves valuation untouched. Aurora CEO Miguel Martin called the application a distraction from the inadequacy of the revised bid.

2.  Federal Registration Reaches Medical Operators Only

The Drug Enforcement Administration has granted federal registration and protections to over 900 medical dispensaries, and nearly 7,000 businesses have applied. The limit sits in how states write licenses. In an Order to Show Cause sent to Minnesota’s In-Dispensary, the DEA refused to register dual-purpose operators that serve medical patients and adult-use customers under one license. That shuts out most of the 24 states with both programs. Registered businesses gain relief from Section 280E, and they must buy product only from registered companies by late November.

AJNA Biosciences applied to the DEA to manufacture marijuana, extracts and THC in bulk for research and trials. No FDA approval exists for any resulting product. Founder Joel Stanley co-founded Charlotte’s Web, and AJNA already holds a DEA registration for psilocybin. Hemp operators face a separate clock, since most federal THC restrictions moved to December 11 while synthetic cannabinoids still face a November 12 ban.

3.  Deal Counts Climb, Checks Shrink

The Viridian Cannabis Deal Tracker counted 74 third quarter transactions, the most since early 2023, yet capital totaled $879 million and the average deal shrank to roughly $12 million. Eighteen of the quarter’s 28 M&A deals disclosed no price. Distress supplied many assets. Cannabist sold its Maryland business under creditor protection, SNDL completed its foreclosure on Parallel’s 56 stores, and PharmaCann’s Maryland licenses go to auction December 7. No large operator tapped the debt market, and 89% of 2026 debt was raised before July.

4.  Q3 Earnings Season Launch

This round of financial and operational results was carried by retail and beverage lines, and pricing pressure was evident in margins and production. Verano reported $212.4 million in revenue, up 5%, with operating cash flow of $49 million, its highest in four years, and a net loss that narrowed to $4.1 million. Its wholesale revenue fell $8 million. Jushi posted $70.5 million in revenue, up 7%, and record wholesale volume, with $215.6 million in gross debt to manage while it prepares for Virginia adult-use sales on July 1, 2027. SNDL delivered record free cash flow of CA$20 million and record retail margins, yet its Cannabis operations booked a $52 million goodwill impairment and entered a strategic review. Tilray lifted revenue 23% to $257.1 million on an 82% jump in beverages, while Cannabis revenue slipped to $56.1 million and net loss reached $40 million.

5.  New York Tops $4B, North Carolina Waits

New York’s regulated market has surpassed $4.1 billion in cumulative retail sales, including $512.6 million in the third quarter, its strongest single quarter. The state counts 1,039 licensed adult-use retailers and has padlocked 738 illegal shops.

In North Carolina, a SurveyUSA poll found 74% support for medical Cannabis and 63% for adult use, yet the House has declined to vote on medical bills the Senate passed. Gov. Josh Stein’s advisory council delivers recommendations by year end. Massachusetts voters decide Question 8 today, a measure that would end licensed adult-use sales, however, the repeal is heading for likely defeat.

6.  Buyers Follow Price & Trust Dispensary Staff

A UC San Diego study used nearly 865,000 point-of-sale records from 10 recreational states and found that a 1% drop in flower prices raised quantity purchased by 2.29%. Median flower prices fell from $8.23 to $6.12 per gram between 2020 and 2023.

A federally funded survey of 1,023 adult users gave dispensary staff a 3.7 on a five-point trust scale, with healthcare providers at 3.4. For medical questions, 55% turned to providers first. For recreational use, 47% turned to dispensary staff.

7.  Optimi & Argent Build Routes Abroad

Optimi Health formed Optimi Australia to sell its psilocybin and MDMA capsules to clinics and pharmacies under the country’s Authorised Prescriber Scheme. Argent BioPharma licensed four proprietary Cannabis genotypes to Thai Phytomed for ten years in return for a 15% royalty on net profits and no upfront payment. Argent shares fell 13.79% on the announcement.

HCN Insight

HCN reads the week through three filters.
The first is federal eligibility. The DEA registers medical-only structures and turns away dual-purpose licenses, so Section 280E relief depends on how a state wrote the license, not on how well a company runs. The second is cash conversion. Verano and SNDL show retail producing liquidity while wholesale and production absorb the damage, and Jushi’s slipping margin points to the pricing pressure behind both. The UC San Diego data explains the mechanism. When shelf prices fall, volume rises, and margin leaves with it. The third is process credibility, which the Aurora contest tests in public. If Aurora’s parallel review yields only standstill agreements by December 4, shareholders have their answer. Viridian’s numbers say capital moves in small tickets, using stock, bank credit and distressed assets, until adult-use scheduling gets a date.
HCN is watching December 4 for Curaleaf’s offer, December 11 for hemp, and the DEA hearing docket.

The winners of this cycle understand two clear fundamentals: consumer wallets are stretched, and strategic capital requires precision. Whether fighting hostile takeovers for global export footprints or developing botanical drug pipelines through standard FDA channels, the industry has abandoned reckless expansion. Long-term equity growth belongs to operators that treat plant medicine not as speculative hype, but as a rigorous, margin-protected manufacturing business.